

Summary Public Assessment Report

Sunitinib Eugia Pharma

(sunitinib malate)

SE/H/2198/01-04/DC

Summary Public Assessment Report

Sunitinib Eugia Pharma
sunitinib malate

Capsule, hard, 12,5 mg, 25 mg, 37,5 mg, 50 mg

This is a summary of the public assessment report (PAR) for Sunitinib Eugia Pharma. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Sunitinib Eugia Pharma and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Sutent.

Sunitinib Eugia Pharma is used to treat adults with the following types of cancer:

- Gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel, where imatinib (another anticancer medicine) no longer works or you cannot take imatinib.
- Metastatic renal cell carcinoma (MRCC), a type of kidney cancer that has spread to other parts of the body.
- Pancreatic neuroendocrine tumours (pNET) (tumours of the hormone-producing cells in the pancreas) that have progressed or cannot be removed with surgery.

How does Sunitinib Eugia Pharma work?

Sunitinib Eugia Pharma contains the active substance sunitinib, which is a protein kinase inhibitor. It is used to treat cancer by preventing the activity of a special group of proteins which are known to be involved in the growth and spread of cancer cells.

How is Sunitinib Eugia Pharma used?

The pharmaceutical form is capsule, hard for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Sunitinib Eugia Pharma have been shown in studies?

Because the product is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Sutent. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Sunitinib Eugia Pharma?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Sunitinib Eugia Pharma approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Sutent, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Sunitinib Eugia Pharma?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Sunitinib Eugia Pharma

The full PAR for Sunitinib Eugia Pharma can be found on the following website: <http://mri.medagencies.org/Human/>. For more information about treatment with Sunitinib Eugia Pharma, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2024-12.